Skip to main content

Table 1 Patient and tumor characteristics of included breast cancer patients undergoing NACT treatment

From: DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival

 

5-year survivors, n = 59*

5-year non-survivors, n = 24*

Age, median (IQR)

 Years

51.5 (44.4 to 56.9)

48.1 (43.9 to 56.8)

Tumor stage, n (%)

 IIB

21 (35.6)

7 (29.2)

 IIIA

24 (40.7)

12 (50.0)

 IIIB

11 (18.6)

3 (12.5)

 IV

3 (5.1)

2 (8.3)

Intrinsic subtype, n (%)

 Basal

5 (9.3)

4 (20.0)

 HER2 enriched

11 (20.4)

5 (25.0)

 Luminal A

12 (22.2)

2 (10.0)

 Luminal B

18 (33.3)

4 (20.0)

 Normal-like

8 (14.8)

5 (25.0)

Treatment response, n (%)

 Partial response

41 (69.5)

11 (45.8)

 Stable disease

18 (30.5)

13 (54.2)

Treatment, n (%)

 Epirubicin

25 (42.4)

8 (33.3)

 Paclitaxel

24 (40.7)

6 (25.0)

 EpiTax**

10 (16.9)

10 (41.7)

  1. *Survivors, n = 59 (24 patients with pre- or post-treatment samples, 35 patients with paired samples). Non-survivors, n = 24 (12 patients with pre- or post-treatment samples, 12 patients with paired samples)
  2. **EpiTax: epirubicin followed by paclitaxel or paclitaxel followed by epirubicin
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us